Parkinson's disease dementia (PDD)(Stage not disclosed)
Catalysts
— October 2026
Status note Lead product candidate. Pivotal Phase 3 early-AD trial (NCT06709014) fully enrolled with 860 patients as of July 2026. Phase 3 PD trial completed December 2023 (topline July 2024); OLE PD study initiated January 2026. FDA approved protocol for a pivotal Phase 3 in PDD (not yet initiated).
Partnerships National Institutes of Health (NIH): conducted and financed the completed single-ascending-dose Phase 1 trial
Indications
Advanced Alzheimer's disease(Phase 1)
Status note Completed single-ascending-dose Phase 1 trial, conducted and financed by NIH.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.